Gamida Cell Ltd (GMDAQ)
OTCMKTS: GMDAQ · Delayed Price · USD
0.0160
-0.0002 (-1.23%)
Apr 30, 2024, 3:38 PM EDT - Market closed
Company Description
Gamida Cell Ltd. researches, develops, and commercializes cell therapies.
The company offers Omisirge (omidubicel-onlv), a cell therapy for use in treatment of patients with hematologic malignancies and severe aplastic anemia.
Its product candidate includes GDA-201, an investigational NK cell-based cancer immunotherapy, for the treatment of hematologic and solid tumors, as well as to treat follicular and diffuse large B-cell lymphomas which is in phase 1 of phase1/2 clinical trial.
The company was incorporated in 1998 and is based in Boston, Massachusetts.
Gamida Cell Ltd
| Country | Israel |
| Founded | 1998 |
| IPO Date | Oct 26, 2018 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 145 |
Contact Details
Address: 5 Nahum Hafzadi Street Jerusalem, L3 95484 Israel | |
| Phone | 97226595666 |
Stock Details
| Ticker Symbol | GMDAQ |
| Exchange | OTCMKTS |
| Fiscal Year | January - December |
| CIK Code | 0001600847 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Abigail L. Jenkins M.S. | President, Chief Executive Officer and Director |
| Mary Theresa Coelho M.B.A. | Chief Financial Officer |
| Dr. Ronit Simantov M.D. | Chief Medical Officer and Chief Scientific Officer |
| Joshua F. Patterson | General Counsel and Chief Compliance Officer |
| Linda Stamler | Vice President of Marketing and Account Management |
| Penny Bushell | Chief Human Resource Officer |
| Naftali Brikashvili CPA | Senior Vice President Finance and Operations |
| Dr. Tracey Lodie Ph.D. | Scientific Advisor and Consultant |
| Vladimir Melnikov | Senior Vice President of Global Operations and Manufacturing |
| Heather DiVecchia | Chief of Staff |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 25, 2024 | 25-NSE | Filing |
| Apr 22, 2024 | 8-K | Current Report |
| Apr 11, 2024 | 8-K/A | [Amend] Current report |
| Apr 5, 2024 | 8-K/A | [Amend] Current report |
| Apr 1, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Mar 29, 2024 | 8-K/A | [Amend] Current report |
| Mar 27, 2024 | 10-K | Annual Report |
| Mar 27, 2024 | 8-K | Current Report |
| Mar 15, 2024 | 8-K | Current Report |
| Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |